Craig Chaya, MD
Ophthalmology · Salt Lake City, UTNPI 1275508160
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. NEW World Medical,inc. accounts for 60.8% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $10,104, more than ten times the $143 reported in 2019. Among ophthalmology clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 52 payments — averaging $317.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$10K
- Nova Eye, Inc.$3K
- Alcon$1K
- AbbVie$1K
- Ivantis, Inc$583
- Aerie Pharmaceuticals, Inc.$125
- plus $313 from 6 others
Across 12 payments — averaging $18,096 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$188K
- AbbVie$29K
What the payments were for
- Consulting fees$3,72523%
- Speaking & faculty fees$9,10055%
- Food & beverage$2,59916%
- Gifts$450%
- Other$1,0396%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 17 | $10,045 |
| Nova Eye, Inc. | 3 | $2,833 |
| Alcon | 6 | $1,390 |
| AbbVie(2 entities) | 14 | $1,218 |
| Ivantis, Inc | 2 | $583 |
| Aerie Pharmaceuticals, Inc. | 1 | $125 |
| Rxsight Inc | 1 | $92 |
| Carl Zeiss Meditec USA, Inc. | 3 | $73 |
| Ocular Therapeutix, Inc. | 1 | $50 |
| Glaukos Corporation | 2 | $49 |
| Bausch & Lomb Americas Inc. | 1 | $33 |
| Sight Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kahook Dual Blade$9,169
- Ahmed Glaucoma Valve$9,169
- Clearpath$8,967
- Streamline$8,967
- Via360$6,193
- Voyager DSLT$1,039
- XEN GLAUCOMA TREATMENT SYSTEM$655
- DURYSTA$550
- LUMIGAN$550
- Hydrus Microstent$500
- Streamline Surgical System$202
- Rhopressa$125
- Rocklatan$125
How this compares
$16,508 in reported general payments places this provider in the 90th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 38 | $15,945 |
| RestasisCyclosporine | 13 | $10,706 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $5,713 |
| Ketorolac Tromethamine | 87 | $4,538 |
| Prednisolone Acetate | 71 | $3,244 |
| Latanoprost | 238 | $2,934 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 121 | $1,714 |
| ValacyclovirValacyclovir Hcl | 15 | $1,612 |
| MoxifloxacinMoxifloxacin Hcl | 48 | $968 |
| Acetazolamide ErAcetazolamide | 17 | $820 |
| Timolol Maleate | 54 | $565 |
| Brimonidine Tartrate | 55 | $483 |
| Dorzolamide Hcl | 29 | $475 |
| Dexamethasone Sodium PhosphateDexamethasone Sodium Phosp/Pf | 20 | $170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $1,218 | $32,36463 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 191 ophthalmology providers in Utah.
Other ophthalmology in Salt Lake City
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
- Austin NakatsukaSalt Lake City$27K
- Douglas MarxSalt Lake City$22K
- Akbar ShakoorSalt Lake City$18K
- Amy LinSalt Lake City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.